Assessment of RAS Dependency for BRAF Alterations Using Cancer Genomic Databases
Authors:
- 4 January 2021
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 4 (1) , e2035479
Abstract
BRAF alterations have been classified into class 1, 2, and 3 based on dimer formation, enzyme activity, and RAS dependence from in vitro experiments.1,2 Different classes of BRAF alterations differ in mechanism of action and require different treatment strategies.3-6 Class 3 alterations are different from class 1 (V600) and class 2 (non-V600 activating alterations) in that they are RAS-dependent with impaired kinase activity.1,2 Class 2 BRAF alterations were defined as RAS independent, and as activating BRAF alterations they are expected to be mutually exclusive to RAS alterations similar to class 1 BRAF alterations. However, some class 2 BRAF alterations were reported to coexist with RAS alterations.7,8 In contrast, class 3 BRAF variants, defined as RAS dependent, can be found without coexisting RAS alterations.7,8 Variation coexistence analysis using cancer genomics database provides evidence for functional interactions between activated RAS and BRAF alterations, and thus can support in vivo RAS dependency or independency. However, such analysis requires a large cancer genomics database, and most published clinical studies are limited in size to systematically assess RAS dependency with real-world clinical data.Keywords
This publication has 17 references indexed in Scilit:
- Faculty Opinions recommendation of BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.2015
- Clinical detection and categorization of uncommon and concomitant mutations involving BRAFBMC Cancer, 2015
- Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant MelanomaJournal of Investigative Dermatology, 2015
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic InhibitionCancer Cell, 2015
- Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanomaMelanoma Research, 2014
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Kinase-Impaired BRAF Mutations in Lung Cancer Confer Sensitivity to DasatinibScience Translational Medicine, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsOncogene, 2008
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004